
Seres Therapeutics (MCRB) P/E Ratio
P/E Ratio as of Jun 30, 2025: -1.11
Average-0.8075
Median-0.7850
Minimum-1.11
Maximum-0.7000
-1.11
Past Month-0.40 (56.34%)
The P/E ratio for Seres Therapeutics (MCRB) is -1.11 as of Jun 30, 2025. This represents a increase of 37.04% compared to its 12-month average P/E ratio of -0.81. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Seres Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Seres Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Seres Therapeutics to industry peers.
Seres Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Seres Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Seres Therapeutics to industry peers.
Seres Therapeutics (MCRB) P/E Ratio Insights
See Seres Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Seres Therapeutics (MCRB)
Order type
Buy in
Order amount
Est. shares
0 shares
Seres Therapeutics (MCRB) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $7.00 | -0.70 |
May 1, 2025 | $9.50 | -0.49 |
Apr 1, 2025 | $13.524 | -1.35 |
Mar 3, 2025 | $14.974 | -0.78 |
Feb 3, 2025 | $16.614 | -0.86 |
Jan 2, 2025 | $16.866 | -0.88 |
Seres Therapeutics (MCRB) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -1.11 | +29.07% |
2024 | -0.86 | -30.65% |
2023 | -1.24 | -47.90% |
2022 | -2.38 | -78.84% |
2021 | -11.25 | -48.32% |
2020 | -21.77 | — |
FAQs About Seres Therapeutics (MCRB) P/E ratio
The latest P/E ratio of Seres Therapeutics (MCRB) is -1.11, as of Jun 30, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Seres Therapeutics’s last 12-month average P/E ratio is -0.81, compared to its current P/E ratio of -1.11. This reflects a increase of 37.04%.
Seres Therapeutics’s current P/E ratio of -1.11 is higher than its last 12-month average P/E of -0.81. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Seres Therapeutics’s average P/E ratio over the last 3 years is -1.88. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Seres Therapeutics’s average P/E ratio over the last 5 years is -6.97. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.